Yang Zhongfei, Deng Fang, Meng Lingjun
Department of Pneumology, Dezhou People's Hospital, Dezhou, Shandong 253000, P.R. China.
Department of Oncology, Dezhou People's Hospital, Dezhou, Shandong 253000, P.R. China.
Exp Ther Med. 2018 Jun;15(6):4856-4860. doi: 10.3892/etm.2018.6010. Epub 2018 Mar 30.
The effect of dendritic cell (DC) immunotherapy on non-small cell lung cancer (NSCLC) and its influence on the distribution of DC subsets were studied. Peripheral blood was drawn from 55 patients, and DCs were cultured and injected into the patients three times. The changes in DC subsets in NSCLC patients before treatment and after three treatments were observed using a flow cytometer, and the difference in DC subsets between patients and healthy controls was compared. DC subsets in lung cancer tissues, para-carcinoma tissues and normal tissues were analyzed by indirect immunofluorescence and laser scanning confocal microscope (LSCM). The BDCA-1 DC1 and BDCA-3 DC2 in lung cancer tissues were significantly increased compared with those in para-carcinoma tissues and normal tissues (P<0.05). The number of DC1 and DC2 in para-carcinoma tissues were increased compared with those in normal tissues (P<0.05). The ratio of DC1 in peripheral blood in the normal control group was obviously higher than that in NSCLC patients (P<0.01). There were significant differences in DC1 and DC1/DC2 ratio in NSCLC patients with different tumor staging, and there were also obvious differences in patients with a different Karnofsky performance status (KPS) score. Moreover, compared with those before treatment, DC1 and DC1/DC2 ratio were significantly increased after three treatments, and there was a significant difference in the comparison of DC1/DC2 ratio between the NSCLC patients with survival time greater than and less than one year. The immune function of NSCLC patients was improved after DC immunotherapy. The survival time of NSCLC patients was closely associated with the DC1/DC2 ratio in peripheral blood. The detection of DC subsets in peripheral blood can help clinicians understand the immune function of NSCLC patients and provide a basis for the clinical judgment of prognosis of NSCLC patients.
研究了树突状细胞（DC）免疫疗法对非小细胞肺癌（NSCLC）的影响及其对DC亚群分布的影响。采集55例患者的外周血，培养DC并分三次注入患者体内。采用流式细胞仪观察NSCLC患者治疗前及三次治疗后的DC亚群变化，并比较患者与健康对照者DC亚群的差异。通过间接免疫荧光和激光扫描共聚焦显微镜（LSCM）分析肺癌组织、癌旁组织和正常组织中的DC亚群。与癌旁组织和正常组织相比，肺癌组织中的BDCA-1 DC1和BDCA-3 DC2显著增加（P<0.05）。癌旁组织中的DC1和DC2数量比正常组织增加（P<0.05）。正常对照组外周血中DC1的比例明显高于NSCLC患者（P<0.01）。不同肿瘤分期的NSCLC患者的DC1和DC1/DC2比值存在显著差异，不同卡氏评分（KPS）的患者也存在明显差异。此外，与治疗前相比，三次治疗后DC1和DC1/DC2比值显著增加，生存时间大于和小于一年的NSCLC患者的DC1/DC2比值比较存在显著差异。DC免疫治疗后NSCLC患者的免疫功能得到改善。NSCLC患者的生存时间与外周血DC1/DC2比值密切相关。检测外周血DC亚群有助于临床医生了解NSCLC患者的免疫功能，为NSCLC患者的预后临床判断提供依据。
